Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy

Clinical Infectious Diseases

Volumn 52, Issue 5, 2011, Pages 604-611

  Wermers, Robert A ^a,b   Cooper, Kay ^c   Razonable, Raymund R ^b,d   Deziel, Paul J ^b   Whitford, Gary M ^f   Kremers, Walter K ^b,c   Moyer, Thomas P ^e  

^a Div of Reproductive Endocrinology   (United States)

^b William J von Liebig Transplant Center   (United States)

^c Department of Radiology ^*  (United States)

^d Division of Infectious Diseases   (United States)

^e MAYO CLINIC   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; FLUORIDE; ITRACONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; BLOOD LEVEL; BONE BIOPSY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; EXOSTOSIS; FEMALE; FLUORIDE BLOOD LEVEL; FLUORIDE BONE LEVEL; FLUOROSIS; GLOMERULUS FILTRATION RATE; HEART GRAFT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; OUTCOME ASSESSMENT; PERIOSTITIS; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTIFUNGAL AGENTS; EXOSTOSES; FEMALE; FLUORIDES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PERIOSTITIS; PLASMA; PYRIMIDINES; TRANSPLANTATION; TRIAZOLES;

EID: 79951828765     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq188     Document Type: Article

References (27)

1. Resnick D. ed. Bone and joint imaging. 2nd ed. Philadelphia, PA: W. B. Saunders Company, 1996.
2. Ismail F. Important fluorinated drugs in experimental and clinical use. J Fluorine Chem 2002;118:27-33.
3. Maienfisch PHR. The importance of fluorine in the life science industry. CHIMIA International Journal for Chemistry. 2004;58:93-9.
4. Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorinecontaining drugs. Annu Rev Pharmacol Toxicol 2001;41:443-70.
5. Whitford GM. Intake and metabolism of fluoride. Adv Dent Res 1994;8:5-14.
6. Taves DR. Determination of submicromolar concentrations of fluoride in biological samples. Talanta 1968;15:1015-23.
7. Whitford GM. The metabolism and toxicity of fluoride. Monogr Oral Sci 1996;16(Rev 2): 24):24-29.
8. Lundy MW, Stauffer M, Wergedal JE, et al. Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoridetreated subjects. Osteoporos Int 1995;5:115-29.
9. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9. (Pubitemid 20094143)
10. Schulz EE, Flowers C, Sauser DD, Brin BN, Wergedal JE, Baylink DJ. The causes of bone scintigram hot spots in fluoride-treated osteoporotic patients. J Bone Miner Res 1990;5(Suppl 1) ; S201-4. (Pubitemid 20284909)
11. Soriano M, Manchon F. Radiological aspects of a new type of bone fluorosis, periostitis deformans. Radiology 1966;87:1089-94.
12. Soriano M. Periostitis deformans. Ann Rheum Dis 1952;11:154-61.
13. Brouwer ID, Dirks OB, De Bruin A, Hautvast JG. Unsuitability of World Health Organization guidelines for fluoride concentrations in drinking water in Senegal. Lancet 1988;1:223-5. (Pubitemid 18044034)
14. Teotia SP, Teotia M. Osteoporosis-India: emerging message. J Assoc Physicians India 1996;44:759-60.
15. Wang LF, Huang JZ. Outline of control practice of endemic fluorosis in China. Soc Sci Med 1995;41:1191-5.
16. Whyte MP, Totty WG, Lim VT, Whitford GM. Skeletal fluorosis from instant tea. J Bone Miner Res 2008;23:759-69. (Pubitemid 351575030)
17. Kurland ES, Schulman RC, Zerwekh JE, Reinus WR, Dempster DW, Whyte MP. Recovery from Skeletal fluorosis (an enigmatic, American case). J Bone Miner Res 2007;22:163-70. (Pubitemid 46032610)
18. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15.
19. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003;31:731-41. (Pubitemid 36617661)
20. Roerig. Product Information: VFEND (R) IV injection, oral tablets, suspension, voriconazole IV injection, oral tablets, solution. Pfizer Inc: New York, 2008.
21. Kharasch ED, Karol MD, Lanni C, Sawchuk R. Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. Anesthesiology 1995;82:1369-78.
22. Levine MF, Sarner J, Lerman J, et al. Plasma inorganic fluoride concentrations after sevoflurane anesthesia in children. Anesthesiology 1996;84:348-53. (Pubitemid 26053834)
23. Wandel C, Neff S, Keppler G, et al. The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans. Anesth Analg 1997;85:924-30. (Pubitemid 27418905)
24. Kraenzlin ME, Kraenzlin C, Farley SM, Fitzsimmons RJ, Baylink DJ. Fluoride pharmacokinetics in good and poor responders to fluoride therapy. J Bone Miner Res 1990;5(Suppl 1) ; S49-52. (Pubitemid 20284885)
25. Rao R, Reddy R. Skeletal fluorosis secondary to occult kidney disease an appraisal. J Assoc Physicians India 1988;36:572-3.
26. Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009;9:2845-50.
27. Chen L, Mulligan ME. Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol 2011;40:143-48.